Chemical formula: C₁₉H₂₅N₅O₄ Molecular mass: 387.433 g/mol PubChem compound: 5401
Although the exact mechanism of the hypotensive action is not established, the relaxation of peripheral blood vessels appears to be produced mainly by competitive antagonism of post-synaptic alpha-adrenoceptors. Terazosin usually produces an initial gradual decrease in blood pressure followed by a sustained antihypertensive action.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| G04CA03 | Terazosin | G Genito urinary system and sex hormones → G04 Urologicals → G04C Drugs used in benign prostatic hypertrophy → G04CA Alpha-adrenoreceptor antagonists |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| HYTRIN Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Terazosin is an active ingredient of these brands:
Austria (AT)Ecuador (EC)
Germany (DE)Hong Kong (HK)Ireland (IE)
Israel (IL)
Italy (IT)Japan (JP)
Netherlands (NL)
Poland (PL)South Africa (ZA)
Spain (ES)Turkey (TR)United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
